229 related articles for article (PubMed ID: 29901116)
1. Retrospective analysis of estrogen receptor 1 and N‑acetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines.
Carlisle SM; Hein DW
Int J Oncol; 2018 Aug; 53(2):694-702. PubMed ID: 29901116
[TBL] [Abstract][Full Text] [Related]
2. High N-Acetyltransferase 1 Expression Is Associated with Estrogen Receptor Expression in Breast Tumors, but Is not Under Direct Regulation by Estradiol, 5
Zhang X; Carlisle SM; Doll MA; Martin RCG; States JC; Klinge CM; Hein DW
J Pharmacol Exp Ther; 2018 Apr; 365(1):84-93. PubMed ID: 29339455
[TBL] [Abstract][Full Text] [Related]
3. Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance.
Minchin RF; Butcher NJ
BMC Genomics; 2018 Jul; 19(1):513. PubMed ID: 29969986
[TBL] [Abstract][Full Text] [Related]
4. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
5. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
6. Quantitative tissue and gene-specific differences and developmental changes in Nat1, Nat2, and Nat3 mRNA expression in the rat.
Barker DF; Walraven JM; Ristagno EH; Doll MA; States JC; Hein DW
Drug Metab Dispos; 2008 Dec; 36(12):2445-51. PubMed ID: 18799802
[TBL] [Abstract][Full Text] [Related]
7. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM
Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.
Hein DW; Doll MA; Fretland AJ; Leff MA; Webb SJ; Xiao GH; Devanaboyina US; Nangju NA; Feng Y
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):29-42. PubMed ID: 10667461
[TBL] [Abstract][Full Text] [Related]
9. N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer.
Lee KM; Park SK; Kim SU; Doll MA; Yoo KY; Ahn SH; Noh DY; Hirvonen A; Hein DW; Kang D
Cancer Lett; 2003 Jul; 196(2):179-86. PubMed ID: 12860276
[TBL] [Abstract][Full Text] [Related]
10. Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity.
Carlisle SM; Trainor PJ; Doll MA; Stepp MW; Klinge CM; Hein DW
Mol Carcinog; 2018 Nov; 57(11):1458-1466. PubMed ID: 29964355
[TBL] [Abstract][Full Text] [Related]
11. Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors.
Wakefield L; Robinson J; Long H; Ibbitt JC; Cooke S; Hurst HC; Sim E
Genes Chromosomes Cancer; 2008 Feb; 47(2):118-26. PubMed ID: 17973251
[TBL] [Abstract][Full Text] [Related]
12. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2.
Smelt VA; Mardon HJ; Sim E
Pharmacol Toxicol; 1998 Oct; 83(4):149-57. PubMed ID: 9820875
[TBL] [Abstract][Full Text] [Related]
13. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
Grant DM; Blum M; Beer M; Meyer UA
Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083
[TBL] [Abstract][Full Text] [Related]
14. Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.
Stepp MW; Doll MA; Carlisle SM; States JC; Hein DW
Mol Carcinog; 2018 Apr; 57(4):549-558. PubMed ID: 29315819
[TBL] [Abstract][Full Text] [Related]
15. Arylamine
Li P; Butcher NJ; Minchin RF
Mol Pharmacol; 2019 Nov; 96(5):573-579. PubMed ID: 31444237
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer.
Kim SJ; Kang HS; Chang HL; Jung YC; Sim HB; Lee KS; Ro J; Lee ES
Oncol Rep; 2008 Mar; 19(3):663-8. PubMed ID: 18288399
[TBL] [Abstract][Full Text] [Related]
17. A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma.
Boissy RJ; Watson MA; Umbach DM; Deakin M; Elder J; Strange RC; Bell DA
Int J Cancer; 2000 Aug; 87(4):507-11. PubMed ID: 10918189
[TBL] [Abstract][Full Text] [Related]
18. Prostate expression of N-acetyltransferase 1 (NAT1) and 2 (NAT2) in rapid and slow acetylator congenic Syrian hamster.
Hein DW; Doll MA; Xiao GH; Feng Y
Pharmacogenetics; 2003 Mar; 13(3):159-67. PubMed ID: 12618593
[TBL] [Abstract][Full Text] [Related]
19. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer.
Endo Y; Yamashita H; Takahashi S; Sato S; Yoshimoto N; Asano T; Hato Y; Dong Y; Fujii Y; Toyama T
BMC Cancer; 2014 Dec; 14():990. PubMed ID: 25528056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
